8:00 am

Morning Coffee

9:00 am Chair’s Opening Remarks

Exploring the Challenges of Tumor Resistance

9:10 am Harnessing Disseminated PDX Models to Advance Drug Discovery for Hematologic Cancers


• Understanding how disease progresses in different tissues in disseminated models
• Recapitulating the bone marrow niche ex vivo to inform in vivo study design
• Employing PDX models to identify clinically actionable combinations

9:30 am Epigenetic Cell Reprograming to Reduce Target Resistance


• Identifying transcription factors which can inhibit reprograming to lessen tumor resistance
• Exploring potential drug combinations which can overcome resistance and prevent tumor growth simultaneously
• Discussing the possibilities of artificial transcription factors to epigenetically target gene expression

10:00 am Leveraging Organoid Models of Breast Cancer Cell Lines to Mimic Growth Inhibition Via CD36+ Fibroblasts

  • Bahram Parvin Director of the Biomedical Engineering, Department of Biomedical Engineering, Cell & Molecular Biology at the University of Reno, Nevada


• Explaining how CD36 expression in fibroblasts is reduced as a result of exposure to the
physiological level of tumor-secreting activin A
• How to utilize co-culture of CD36+ fibroblast cells (FB) with the organoid models of MDAMB-
231 to induce growth inhibition
• Distinguish co-culture of CD36+ FB with the MCF7 breast cancer cell lines to show the
reversion of aberrant lateral and basal polarities
• Discussing the mechanism of tumorigenicity and the relevance to colony growth inhibition
and polarity reversion

10:20 am Panel Discussion: Tissue Sample Heterogeneity – Utilizing Cell Lines to Ensure Minimal Tumor Variation & Promote Clinical Efficacy

  • Sarah Knutson Director of Preclinical Biology, Twenty Eight- Seven Therapeutics


• Explore how to harness cell lines to tackle the challenges surrounding cancer heterogeneity
• Produce a framework of how to overcome target resistance to produce an efficacious therapy

11:00 am

Morning Break

Deep Diving into the Next Generation of Preclinical Tumor Models

11:45 am Combination Approach: Using Chicken Egg In Vitro Cell Cultures for High-Value Identification of Oncology Candidates


• How to use INOVOTION’s technology to open new perspectives of in vivo screening in oncology and immuno-oncology
• Why does the chicken embryo model have several advantages for drug discovery of anti-cancer treatments over traditional in vivo models?
• The chicken embryo model fills the gap between in vitro studies and in vivo mouse models, but is it possible to predict mouse data from chicken embryo results?

12:15 pm Utilizing & Translating CAR-T Cell Therapy to Solid Tumors


• Discuss the challenges surrounding the clinical activity of CAR-T cell therapy in solid tumors
• Exploring the degree of model translatability between preclinical studies and human CAR-T cell trials
• Next-generation CART cell therapy approaches combining novel targets with endogenous immune modulation

12:35 pm Live Q&A – Ask Speakers Your Burning Questions

1:15 pm

Networking Lunch

Analyzing Preclinical Toxicity, Safety & Dose Translation

2:15 pm Brain Tumor Models as a Platform to Advance Functional Diagnostics & Clinical Trials

  • Keith Ligon Director - Center For Patient Derived Models, Principal Investigator, Neuropathologist & Pathologist, Dana-Farber Cancer Institute


• Models of primary and metastatic brain cancer are highly valuable tools for precision medicine and preclinical testing
• Large number of common and rare brain cancer models allow large scale drug screening
• Novel approaches and technologies emerging to test patient models to personalize medicine and trials

2:35 pm Harnessing Genome-scale In Vivo T-Cell CRISPR Screen to Identify Novel Immuno-Oncology Targets For the Treatment of Solid Tumors

  • Louise Cadzow Senior Director, Head of In Vivo Pharmacology, KSQ Therapeutics


• Developed a novel CRISPRomics® platform that enabled in vivo genome-wide CRISPR/Cas9 screens in primary T-cells
• Systematic identification and validation of targets that can significantly improve T-cell function in solid tumor setting
• Developed CRISPR2 technology that enables the identification of optimal T-cell target combinations that drive anti-tumor response

2:55 pm Live Q&A – Ask the Speakers Your Burning Questions

3:40 pm Chair’s Closing Remarks & End of Conference